Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyResearch in context

MLA

Marwan Fakih, et al. “Regorafenib plus Nivolumab in Patients with Mismatch Repair-Proficient/Microsatellite Stable Metastatic Colorectal Cancer: A Single-Arm, Open-Label, Multicentre Phase 2 StudyResearch in Context.” EClinicalMedicine, vol. 58, no. 101917-, Apr. 2023. EBSCOhost, https://doi.org/10.1016/j.eclinm.2023.101917.

APA

Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D’Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, … Andrew Scott Paulson. (2023). Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyResearch in context. EClinicalMedicine, 58(101917-). https://doi.org/10.1016/j.eclinm.2023.101917

Chicago

Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, et al. 2023. “Regorafenib plus Nivolumab in Patients with Mismatch Repair-Proficient/Microsatellite Stable Metastatic Colorectal Cancer: A Single-Arm, Open-Label, Multicentre Phase 2 StudyResearch in Context.” EClinicalMedicine 58 (101917-). doi:10.1016/j.eclinm.2023.101917.